Match!
Lars Bauer
UCB
Physical therapyPlaceboTransdermal patchRotigotineMedicine
44Publications
10H-index
332Citations
What is this?
Publications 44
Newest
#1Xenofon Baraliakos (RUB: Ruhr University Bochum)H-Index: 42
#2Torsten Witte (MHH: Hannover Medical School)H-Index: 50
Last. Lars Bauer (UCB)H-Index: 10
view all 11 authors...
OBJECTIVES The efficacy and safety of certolizumab pegol (CZP), an Fc-free, PEGylated anti-TNF, in axial spondyloarthritis (axSpA) has been established in clinical trial settings. We report CZP effectiveness and safety in European clinical practice in patients with axSpA, including radiographic (r-) and non-radiographic (nr-) axSpA. METHODS CIMAX (NCT02354105), a European non-interventional multicentre prospective study, observed CZP treatment response and safety over 12 months in a real-world a...
Source
#1Robert LandewéH-Index: 5
#2Désirée van der Heijde (LUMC: Leiden University Medical Center)H-Index: 91
Last. Karen Thomas (UCB)H-Index: 1
view all 11 authors...
INTRODUCTION Achievement of remission is a key treatment goal for patients with axial spondyloarthritis (axSpA). C-OPTIMISE assessed achievement of sustained clinical remission in patients with axSpA, including radiographic (r) and non-radiographic (nr) axSpA, during certolizumab pegol (CZP) treatment, and subsequent maintenance of remission following CZP dose continuation, dose reduction or withdrawal. Here, we report outcomes from the first 48 weeks (induction period) of C-OPTIMISE, during whi...
Source
#1R. B. M. LandewéH-Index: 53
#1Robert LandewéH-Index: 66
Last. Karen Thomas (UCB)H-Index: 1
view all 11 authors...
Background: Previous studies have shown that withdrawing tumour necrosis factor inhibitors (TNFi) in patients (pts) with axial spondyloarthritis (axSpA) who have achieved sustained remission often leads to relapse.1 However, none have formally tested TNFi dose reduction strategies in a broad axSpA population or evaluated whether relapse following TNFi dose reduction and withdrawal is associated with a specific demographic subgroup. Objectives: C-OPTIMISE evaluated the percentage of pts without f...
Source
#1Robert LandewéH-Index: 66
#2D. van der Heijde (LUMC: Leiden University Medical Center)H-Index: 41
Last. Natasha de Peyrecave (UCB)H-Index: 3
view all 12 authors...
BACKGROUND: The best strategy for maintaining clinical remission in patients with axial spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, reduction and withdrawal of the tumour necrosis factor inhibitor certolizumab pegol (CZP) following achievement of sustained remission in patients with early axSpA. METHODS: C-OPTIMISE was a two-part, multicentre phase 3b study in adults with early active axSpA (radiographic or non-radiographic). During the 48-week open-lab...
2 CitationsSource
#1I E van der Horst-Bruinsma (UvA: University of Amsterdam)H-Index: 29
#1Irene E. van der Horst-Bruinsma (UvA: University of Amsterdam)H-Index: 15
Last. Lars Bauer (UCB)H-Index: 10
view all 11 authors...
BACKGROUND: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in patients with axial spondyloarthritis (axSpA). C-VIEW investigates the impact of the Fc-free TNF inhibitor certolizumab pegol (CZP) on AAU flares in patients with active axSpA at high risk of recurrent AAU. METHODS: C-VIEW (NCT03020992) is a 96-week ongoing, multicentre, open-label, phase 4 study. Included patients had an axSpA diagnosis, a history of recurrent AAU (>/=2 AAU flares, >/=1 flare in the yea...
2 CitationsSource
#1Raj Sengupta (Royal National Hospital for Rheumatic Diseases)H-Index: 11
#2Lianne S. Gensler (UCSF: University of California, San Francisco)H-Index: 19
Last. Atul Deodhar (OHSU: Oregon Health & Science University)H-Index: 35
view all 10 authors...
Source
#1Karl Gaffney (Norfolk and Norwich University Hospitals NHS Foundation Trust)H-Index: 3
#2Atul Deodhar (OHSU: Oregon Health & Science University)H-Index: 35
Last. Lars Bauer (UCB)H-Index: 10
view all 14 authors...
Source
#1Atulya (Atul) Deodhar (OHSU: Oregon Health & Science University)H-Index: 21
#2Lianne S. Gensler (UCSF: University of California, San Francisco)H-Index: 19
Last. D. van der Heijde (LUMC: Leiden University Medical Center)H-Index: 41
view all 13 authors...
Objective: The natural history of nonradiographic axial spondyloarthritis (SpA) is incompletely characterized, and there are concerns that nonsteroidal antiinflammatory drugs provide inadequate disease control in patients with active disease. This study was undertaken to investigate the effects of certolizumab pegol (CZP), an anti–tumor necrosis factor treatment, in patients with nonradiographic axial SpA with objective signs of inflammation. Methods: In this ongoing parallel-group double-blind ...
15 CitationsSource
#1Robert LandewéH-Index: 66
#2D. van der Heijde (LUMC: Leiden University Medical Center)H-Index: 41
Last. Lianne S. Gensler (UCSF: University of California, San Francisco)H-Index: 19
view all 11 authors...
Background C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained remission after 48 weeks’ (wks’) treatment. Objectives Here, we report interim efficacy and safety data for both subpopulations from the ongoing trial. Methods Up to Wk48 , C-OPTIMISE (NCT02505542) was open-label (Part A), followed by 48-wk parallel-group, double-blin...
Source
#1Laura C. Coates (NOC: Nuffield Orthopaedic Centre)H-Index: 1
#1L C Coates (NOC: Nuffield Orthopaedic Centre)H-Index: 3
Last. D. van der Heijde (LEI: Leiden University)H-Index: 41
view all 12 authors...
Background: Psoriatic arthritis Disease activity Score (PASDAS),1Disease activity index for Psoriatic arthritis (DAPSA),2 and the minimal disease activity (MDA) criteria3 are instruments recommended for evaluating disease activity (DA) in psoriatic arthritis (PsA). RAPID-PsA demonstrated the sustained efficacy of certolizumab pegol (CZP) across the spectrum of PsA symptoms.4 a substantial proportion of patients (pts) completing 4 years’ treatment achieved DA targets; ∼75% reached DAPSA low DA (L...
1 CitationsSource
12345